Innovative Leukemia and Lymphoma Therapy

Overview

Innovative Leukemia and Lymphoma Therapy provides a complete and up-to-date overview of the exciting new treatment modalities in leukemia and lymphoma that are being introduced in the clinic today. Written by international experts in the field, this volume examines clinical studies on topics such as:

  • tyrosine kinase inhibitors, histon ...
See more details below
Available through our Marketplace sellers.
Other sellers (Hardcover)
  • All (5) from $196.59   
  • New (4) from $196.59   
  • Used (1) from $253.29   
Close
Sort by
Page 1 of 1
Showing All
Note: Marketplace items are not eligible for any BN.com coupons and promotions
$196.59
Seller since 2008

Feedback rating:

(4442)

Condition:

New — never opened or used in original packaging.

Like New — packaging may have been opened. A "Like New" item is suitable to give as a gift.

Very Good — may have minor signs of wear on packaging but item works perfectly and has no damage.

Good — item is in good condition but packaging may have signs of shelf wear/aging or torn packaging. All specific defects should be noted in the Comments section associated with each item.

Acceptable — item is in working order but may show signs of wear such as scratches or torn packaging. All specific defects should be noted in the Comments section associated with each item.

Used — An item that has been opened and may show signs of wear. All specific defects should be noted in the Comments section associated with each item.

Refurbished — A used item that has been renewed or updated and verified to be in proper working condition. Not necessarily completed by the original manufacturer.

New
New Book. Shipped from UK within 4 to 14 business days. Established seller since 2000.

Ships from: Horcott Rd, Fairford, United Kingdom

Usually ships in 1-2 business days

  • Standard, 48 States
  • Standard (AK, HI)
$200.64
Seller since 2007

Feedback rating:

(2985)

Condition: New
2008 Hardcover Binding: Hard Cover. Brand new, unused book. 598 pp. -Brand new, unused.

Ships from: San Jose, CA

Usually ships in 1-2 business days

  • Canadian
  • International
  • Standard, 48 States
  • Standard (AK, HI)
  • Express, 48 States
  • Express (AK, HI)
$211.48
Seller since 2009

Feedback rating:

(10075)

Condition: New
New Book. Shipped from US within 4 to 14 business days. Established seller since 2000

Ships from: Secaucus, NJ

Usually ships in 1-2 business days

  • Standard, 48 States
  • Standard (AK, HI)
$242.63
Seller since 2007

Feedback rating:

(23307)

Condition: New
BRAND NEW

Ships from: Avenel, NJ

Usually ships in 1-2 business days

  • Canadian
  • International
  • Standard, 48 States
  • Standard (AK, HI)
Page 1 of 1
Showing All
Close
Sort by
Sending request ...

Overview

Innovative Leukemia and Lymphoma Therapy provides a complete and up-to-date overview of the exciting new treatment modalities in leukemia and lymphoma that are being introduced in the clinic today. Written by international experts in the field, this volume examines clinical studies on topics such as:

  • tyrosine kinase inhibitors, histon deacetylase inhibitors, and farnesyl transferase inhibitors
  • radioimmunotherapy, gene-directed therapy, and immunotherapy by vaccination
  • monoclonal antibodies
  • anti-angiogenesis approaches

Within each chapter, this well-illustrated, comprehensive source provides a summary of the rationale for treatment, the pathways that are involved, and the translational research to students, scientists, and clinicians. In addition, this book focuses on the concerns of conventional but novel anticancer agents, modulation of classical multidrug resistance, and modulators of single agent drug resistance.

Read More Show Less

Product Details

  • ISBN-13: 9780849350832
  • Publisher: Taylor & Francis
  • Publication date: 5/21/2008
  • Series: Basic and Clinical Oncology Series
  • Pages: 616
  • Product dimensions: 6.10 (w) x 9.10 (h) x 1.50 (d)

Meet the Author

Gertjan J. L. KASPERS is Professor and Head of the Division of Oncology/Hematology, VU University Medical Center, Amsterdam, Netherlands. Dr. Kaspers received his M.D. from the Vrije Universiteit, Amsterdam, Netherlands, and his Ph.D. from the VU University Medical Center, Amsterdam, Netherlands. His current research covers a randomized phase III study on the treatment of children and adolescents with refractory or relapsed acute myeloid leukemia, a phase II study on Mylotarg in childhood relapsed and refractory AML, an international study on the treatment of Pediatric Acute Promyelocytic Leukemia, clinical phase II studies with clofarabine-containing regimens in pediatric acute myeloid leukemia, and a clinical phase II study with bortezomib in pediatric acute lymphoblastic leukemia in preparation.

BERTRAND COIFFIER is Professor and Chief of Hematology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon and Claude-Bernard University, Pierre-Benite, France. Dr. Coiffier has written more than 300 publications in internationally recognized, leading journals in the field of hematology on lymphomas, lymphoproliferative diseases, chemotherapy, high-dose therapy, and autotransplant, biological response modifiers.

MICHAEL C. HEINRICH is Professor of Medicine, Oregon Health & Science University, Division of Hematology & Medical Oncology, Portland, Oregon, USA; Chairman, Portland VA Medical Center Tumor Board, Section Chief, Hematology Oncology, Portland VA Hematology/Medical Oncology Service, Portland, Oregon, USA; and Interim Head, Hematology & Medical Oncology, Oregon Health & Science University, Portland, Oregon, USA. Dr. Heinrich received his M.D. from the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. ELIHU ESTEY is Professor of Hematology in the Division of Medicine at the University of Washington Medical Center and a Member at the Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. Dr. Estey received his A.B. from Yale University, New Haven, Connecticut, USA, and his M.D. from Johns Hopkins University, Baltimore, Maryland, USA.

Read More Show Less

Table of Contents

Foreword Bob Lowenberg Lowenberg, Bob

1 Gene Expression Profiling to Detect New Treatment Targets in Leukemia and Lymphoma: A Future Perspective Torsten Haferlach Haferlach, Torsten Wolfgang Kern Kern, Wolfgang Alexander Kohlmann Kohlmann, Alexander 1

2 Individualized Tumor Response Testing in Leukemia and Lymphoma Andrew G. Bosanquet Bosanquet, Andrew G. Peter Nygren Nygren, Peter Larry M. Weisenthal Weisenthal, Larry M. 23

3 Minimal Residual Disease Jacques J. M. van Dongen van Dongen, Jacques J. M. Tomasz Szczepanski Szczepanski, Tomasz Vincent H. J. van der Velden van der Velden, Vincent H. J. 45

4 New Methods for Clinical Trials: AML as an Example Elihu Estey Estey, Elihu 85

5 Monoclonal Antibody Mediated Treatment in Acute Myeloid Leukemia Ch. Michel Zwaan Zwaan, Ch. Michel Many M. van den Heuvel-Eibrink van den Heuvel-Eibrink, Many M. 99

6 Monoclonal Antibodies in the Treatment of Malignant Lymphomas and Chronic Lymphocytic Leukemia Bertrand Coiffier Coiffier, Bertrand 125

7 Radioimmunotherapy of Hematological Malignancies Tim Illidge Illidge, Tim James Hainsworth Hainsworth, James 149

8 Differentiation Induction in Acute Promyelocytic Leukemia Adi Gidron Gidron, Adi Martin S. Tallman Tallman, Martin S. 185

9 DNA Methylation and Epigenetics: New Developments in Biology and Treatment Jesus Duque Duque, Jesus Michael Lubbert Lubbert, Michael Mark Kirschbaum Kirschbaum, Mark 207

10 The Emerging Role of Histone Deacetylase Inhibitors in the Treatment of Lymphoma Matko Kalac Kalac, Matko Owen A. O'Connor O'Connor, Owen A. 233

11 Antileukemic Treatment Targeted at Apoptosis Regulators Simone Fulda Fulda, Simone Klaus-Michael Debatin Debatin,Klaus-Michael 257

12 Angiogenesis in Hematological Malignancies Alida C. Weidenaar Weidenaar, Alida C. Hendrik J. M. de Jonge de Jonge, Hendrik J. M. Arja ter Elst Elst, Arja ter Evelina S. J. M. de Bont de Bont, Evelina S. J. M. 283

13 Nucleic Acid-Based, mRNA-Targeted Therapeutics for Hematologic Malignancies Alan M. Gewirtz Gewirtz, Alan M. 311

14 Active Specific Immunization by the Use of Leukemic Dendritic Cell Vaccines Ilse Houtenbos Houtenbos, Ilse Gert J. Ossenkoppele Ossenkoppele, Gert J. Arjan A. van de Loosdrecht van de Loosdrecht, Arjan A. 329

15 CDK Inhibitors in Leukemia and Lymphoma Yun Dai Dai, Yun Steven Grant Grant, Steven 353

16 FLT3: A Receptor Tyrosine Kinase Target in Adult and Pediatric AML Mark Levis Levis, Mark Patrick Brown Brown, Patrick Donald Small Small, Donald 379

17 Treatment of Chronic Myeloid Leukemia with Bcr-Abl Kinase Inhibitors Michael J. Mauro Mauro, Michael J. Michael C. Heinrich Heinrich, Michael C. 411

18 Tyrosine Kinase Inhibitors: Targets Other Than FLT3, BCR-ABL, and c-KIT Suzanne R. Hayman Hayman, Suzanne R. Judith E. Karp Karp, Judith E. 429

19 Tyrosine Phosphatases as New Treatment Targets in Acute Myeloid Leukemia I. Hubeek Hubeek, I. K. Hoorweg Hoorweg, K. J. Cloos Cloos, J. Gertjan J. L. Kaspers Kaspers, Gertjan J. L. 449

20 Proteasome and Protease Inhibitors N. E. Franke Franke, N. E. J. Vink Vink, J. J. Cloos Cloos, J. Gertjan J. L. Kaspers Kaspers, Gertjan J. L. 469

21 Farnesyltransferase Inhibitors: Current and Prospective Development for Hematologic Malignancies Judith E. Karp Karp, Judith E. 491

22 Targeting Notch Pathways Jennifer O'Neil O'Neil, Jennifer A. Thomas Look Look, A. Thomas 513

23 mTOR Targeting Agents for the Treatment of Lymphoma and Leukemia Andrea E. Wahner Hendrickson Hendrickson, Andrea E. Wahner Thomas E. Witzig Witzig, Thomas E. Scott H. Kaufmann Kaufmann, Scott H. 525

24 Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning Frederic Baron Baron, Frederic Frederick R. Appelbaum Appelbaum, Frederick R. Brenda M. Sandmaier Sandmaier, Brenda M. 539

25 Modulation of Classical Multidrug Resistance and Drug Resistance in General Branimir I. Sikic Sikic, Branimir I. 563

Index 581

Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)